Closed Clinical Trials

A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients with Node-Negative Breast Cancer (NSABP B-36)

A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed By Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Previously Untreated, Stage III (Suboptimal) and All Stage IV, Epithelial, Ovarian or Primary Peritoneal Cancer (GOG-0218)

A Randomized Phase III Trial of Exemestane vs Anastrozole in post menopausal women w/receptor positive primary breast CA (MA. 27)

Axillary positive or high risk node negative Breast Ca adjuvant therapy using doxetaxel and cyclophosphamide followded by paclitaxel or docetaxel weekly q 12 weeks vs q 3 weeks for 4 cycles. (ECOG1199 )

A Three-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC->T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere and Cyclophosphamide (ATC) in Breast Cancer Patients with Positive Axillary Lymph Nodes (NSABP-30)

A Randomized study to prevent Lymphedema in Women Treated for Breast Cancer – Education only (CALGB 70305)

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (ECOG-ACRIN E3A06) (Closed to enrollment)
Sponsor: Federal
Principle Investigator: Renee E. Funches, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Multinational, Phase 3, Randomized, Double-Blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (Closed to enrollment)
Sponsor: Industry
Principle Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease (Closed to enrollment)
Sponsor: Industry
Principle Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer (NSABP B-47) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Phase II, single arm study of the use of steroid-based mouthwash to prevent stomatitis in postmenopausal women with advanced or metastatic hormone receptor positive breast cancer being treated with everoimus plus exemestane (STOPP) (Closed to enrollment)
Sponsor: Industry
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI) Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer (SWOG S1202) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Mahrukh Hussain, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

Statin Polyp Prevention Trial in Patients with Resected Colon Cancer (NSABP P-5) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

Phase III Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy (NSABP B-43) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed following Carboplatin, Paclitaxel and Bevacizizumab for Advanced Non-Squamous NSCLC (ECOG E5508) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer, For Patients with Bone Metastases from Breast Cancer, Prostate Cancer or Multiple Myeloma (CALGB 70604) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus CELECOXIB or PLACEBO for Patients with Resected Stage III Colon Cancer (CALGB/SWOG C80702) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (NSABP B49) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score of 25 or Less (SWOG S1007) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC->P); DD AC Followed By DD Paclitaxel Plus Gemcitabine (DD AC->PG) (NSABP B-38) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer ( IBCSG 24-02) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy (NSABP-35) (Long Term Follow Up)
Sponsor: Federal
Principal Investigator: Aloysius Pereira, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer ( SWOG-S0307) (Closed to enrollment)
Sponsor: Federal
Principal Investigator: Leon Hwang, MD
Contact: Leslie Greenberg, Clinical Trial Manager, 301-816-6768

An Open-label, Multicenter Study of the Long-Term Efficacy, Safety and Tolerability of BOTOX (Onabotulinumtoxin A) for the Prophylaxis of Headaches in Adult Patients with Chronic Migraine (Closed to enrollment)
Sponsor: Industry
Principal Investigator: Ejaz Shamim, MD
Contact: Aundria Charles, 301-928-8870

eNeura SpringTMS Post-Market Observational U.S. Study of Migraine (Closed to enrollment)
Sponsor: Industry
Principal Investigator: Ejaz Shamim, MD
Contact: Aundria Charles, 301-928-8870

A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment (Closed to enrollment)
Sponsor: Industry
Principal Investigator: Bradley Winston, MD
Contact: Linda Steeby, 703-922-1310